249 related articles for article (PubMed ID: 19604433)
1. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients.
Matsumura R; Umemiya K; Sugiyama T; Sueishi M; Umibe T; Ichikawa K; Yoshimura M;
Clin Exp Rheumatol; 2009; 27(3):416-21. PubMed ID: 19604433
[TBL] [Abstract][Full Text] [Related]
2. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
4. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
6. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
7. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.
Gottenberg JE; Merle-Vincent F; Bentaberry F; Allanore Y; Berenbaum F; Fautrel B; Combe B; Durbach A; Sibilia J; Dougados M; Mariette X
Arthritis Rheum; 2003 Jul; 48(7):2019-24. PubMed ID: 12847696
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis.
Hayat SJ; Uppal SS; Narayanan Nampoory MR; Johny KV; Gupta R; Al-Oun M
Clin Rheumatol; 2007 Jun; 26(6):973-5. PubMed ID: 16565897
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus.
Hayat SJ; Uppal SS
Mod Rheumatol; 2007; 17(2):174-7. PubMed ID: 17437178
[TBL] [Abstract][Full Text] [Related]
12. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
13. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
Cardiel MH; Tumlin JA; Furie RA; Wallace DJ; Joh T; Linnik MD;
Arthritis Rheum; 2008 Aug; 58(8):2470-80. PubMed ID: 18668592
[TBL] [Abstract][Full Text] [Related]
14. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
15. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
16. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.
Subramanian S; Yajnik V; Sands BE; Cullen G; Korzenik JR
Inflamm Bowel Dis; 2011 Jan; 17(1):99-104. PubMed ID: 20629183
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG.
Silvestris F; D'Amore O; Cafforio P; Savino L; Dammacco F
Clin Exp Immunol; 1996 May; 104 Suppl 1():91-7. PubMed ID: 8625551
[TBL] [Abstract][Full Text] [Related]
18. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
19. Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature.
Shovman O; Tamar S; Amital H; Watad A; Shoenfeld Y
Clin Rheumatol; 2018 Feb; 37(2):563-568. PubMed ID: 29063464
[TBL] [Abstract][Full Text] [Related]
20. Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis.
Spertini F; Leimgruber A; Morel B; Khazaeli MB; Yamamoto K; Dayer JM; Weisbart RH; Lee ML
J Rheumatol; 1999 Dec; 26(12):2602-8. PubMed ID: 10606369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
